Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Reexamination Certificate
2011-04-20
2011-10-18
Padmanabhan, Sreeni (Department: 1627)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
C564S123000, C564S308000, C564S427000, C568S306000
Reexamination Certificate
active
08039515
ABSTRACT:
Methods for concomitant administration of colchicine together with one or more macrolide antibiotics, e.g., clarithromycin, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits.
REFERENCES:
patent: 5758095 (1998-05-01), Albaum et al.
patent: 5833599 (1998-11-01), Schrier et al.
patent: 5845255 (1998-12-01), Mayaud
patent: 5914332 (1999-06-01), Sham et al.
patent: 6014631 (2000-01-01), Teagarden et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6067524 (2000-05-01), Byerly et al.
patent: 6112182 (2000-08-01), Akers et al.
patent: 6317719 (2001-11-01), Schrier et al.
patent: 6356873 (2002-03-01), Teagarden et al.
patent: 7072840 (2006-07-01), Mayaud
patent: 7601758 (2009-10-01), Davis
patent: 7619004 (2009-11-01), Davis
patent: 7820681 (2010-10-01), Davis
patent: 7906519 (2011-03-01), Davis
patent: 7915269 (2011-03-01), Davis
patent: 7935731 (2011-05-01), Davis
Wang et al. 2001, “HMG-CoA reductase inhibitors (Statins) characterized as direct inhibitors of P-glycoprotein.” Pharmaceutical Research, vol. 18, No. 6, pp. 800-806.
U.S. Appl. No. 12/687,406, filed Jan. 2010, Davis, Matthew W.
U.S. Appl. No. 12/407,980, filed Mar. 2009, Davis, Matthew W.
U.S. Appl. No. 12/688,038, filed Jan. 2010, Davis, Matthew W.
U.S. Appl. No. 12/576,355, filed Oct. 2009, Davis, Matthew W.
U.S. Appl. No. 12/909,171, filed Oct. 2010, Davis, Matthew W.
U.S. Appl. No. 12/545,120, filed Aug. 2009, Davis, Matthew W.
U.S. Appl. No. 13/092,459, filed Apr. 2011, Davis, Matthew W.
U.S. Appl. No. 13/109,034, filed May 2011, Davis, Matthew W.
U.S. Appl. No. 13/110,087, filed May 2011 Davis, Matthew W.
Cheng, et al.; “Two Probable Cases of Serious Drug Interaction Between Clarithromycin and Colchicine”; Southern Medical Journal; p. 811, (2005).
Horn, et al.; “Life-threatening Colchicine Drug Interactions”; Pharmacy Times; p. 111; (2006).
Hung et al.; “Fatal Interaction Between Clarithromycin and Colchicine in Patients with Renal Insufficiency: A Retrospective Study”; Clinical Infectious Diseases; 41; pp. 291-300; (2005).
Leikin ete al.; “Colchicine”; Poisoning and Toxicology Handbook, Fourth Edition; p. 216; (2007).
Perez-Ruiz, et al.; “Optimisation of the Treatment of Acute Gout”; BioDrugs; 13; pp. 415-423; (2000).
Rollot, et al.; “Acute Colchicine Intoxication During Clarithromycin Administration”; The Annals of Pharmacotherapy; 38; pp. 2074-2077; (2004).
Terkeltaub, Robert A.; “Gout”; The New England Journal of Medicine; 349; pp. 1647-1655; (2003).
Terkeltaub, et al.; “Comparison of Low-Dose vs High-Dose Oral Colchicine Regimens in Patients with Gout Flares”; Prescentation at the American College of Rheumatology Scientific Meeting; San Francisco, CA; Oct. 24-29; (2008).
Terkeltaub, et al.; “The Clinical Relevance of P-gp and CYP 3A4 on Colchicine Metabolism and Elimination”; Presentation at the American College of Rheumatology Scientific Meeting; San Francisco, CA; Oct. 24-29; (2008b).
Van Der Velden, et al.; “Colchicine-Induced Neuromyopathy in a Patient with Chronic Renal Failure: The Role of Clarithromycin”; Netherlands Journal of Medicine; 66; pp. 204-206; (2008).
Waknine, Yael; “FDA Safety Changes: Dexedrine and Biaxin CME/CE”; Medscape Medical News; http://bcbsma.medscape.com/viewarticle/54411; 5 pages; (2006).
Clarithromycin Tablets, USP; Clarithromycin for Oral Suspension, USP, BIAXIN XL Filmtab; Abbott Laboratories; 07E-010-U780-4 Master; 26 pages; Reference 03-5569-R3 Revised Mar. 2007.
Concomitant Drugs (Wikidpedia document) http://en.wikipedia.org/wiki/Concomitant—drugs; printed May 28, 2009, 2 pages.
Drugs.com; “Colchicine Dosage” (available on line http://www.drugs.com/dosage/colchicine.html); 6 pages; accessed Sep. 20, 2010.
Krishnan et al.; “Gout in Ambulatory Care Settings in the United States”; Journal of Rheumatology; 35; pp. 498-501; (2008).
Lacy et al.; Lexi-Comp's Clinical Reference Library, Drug Information Handbook, 7th Ed., pp. 108-109 and 292-293; (1999-2000).
Morris, et al.; “Lesson of the Week—Colchicine in Acute Gout”; BMJ; 327; pp. 1275-1276; (2003).
U.S. Appl. No. 12/327,258 Final Office Action dated Apr. 16, 2009; 24 pages.
U.S. Appl. No. 12/327,258 Non-final Office Action dated Feb. 13, 2009; 20 pages.
U.S. Appl. No. 12/327,258 Final Office Action dated Jul. 24, 2009; 22 pages.
U.S. Appl. No. 12/327,258 Non-final Office Action dated Jun. 4, 2009; 33 pages.
U.S. Appl. No. 12/368,700 Non-final Office Action dated Apr. 27, 2009, 77 pages.
Ogbru, Omudhome (www.medicinenet.com/colchicine/article.htm; 2 pages; (2008).
Rango; “Management of Goup with Colchicine”; http://www.theberries.ca/Archives/colchicine.html; 4 pages; available on line as of Jul. 5, 2003).
Rx-s.net/weblog/more/colchicine-indications-and-dosage/; “Colchicine Indications and Dosage”; 5 pages; last revised Aug. 2, 2005.
Akdag et al.; “Acute Colchicine Intoxication During Clarithromycin Administration in Patients With Chronic Renal Failure”; J. Nephrol; 19; pp. 515-517; (2006).
Caraco, et al.; Acute Colchicine Intoxication—Possible Role of Erythromycin Administration; Journal of Rheumatology; 19:3; pp. 494-496; (1992).
“Colchicine: Serious Interactions”; prepared by editorial staff; Translated from Rev. Prescrire; 28(294); pp. 267-270); (2008).
Dogukan et al.; “Acute Fatal Colchicine Intoxication in a Patient on Continuous Ambulatory Peritoneal Dialysis (CAPD). Possible Role of Clarithromycin Administration”; Clinical Nephrology; 55(2); pp. 181-182; (2001).
Cantor & Colburn LLP
McMillian Kara R
Mutual Pharmaceutical Company, Inc.
Padmanabhan Sreeni
LandOfFree
Methods for concomitant administration of colchicine and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for concomitant administration of colchicine and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for concomitant administration of colchicine and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4277244